Psychedelics in Psychiatry-Keeping the Renaissance From Going Off the Rails.
JAMA Psychiatry May 1, 2021 David B. Yaden, Mary E. Yaden, Roland R. Griffiths 102 citations
No Summary
Mary E. Yaden
6 papers in the library · 138 citations · publishing 2021-2026
Papers
What Is in a Name? The Many Meanings of "Psychedelic".
Psychedelic Med (New Rochelle) December 13, 2023 Kelley C O'Donnell, Daniel E. Roberts, Terence H. W. Ching et al. 13 citations
The term 'psychedelic' carries multiple, sometimes conflicting, meanings across different contexts—scientific, cultural, legal, and historical. This ambiguity can hinder clear communication and slow research progress by creating misunderstandings among researchers, clinicians, policymakers, and the public. The authors argue that recognizing and clarifying these varied definitions is essential for advancing the field, as precise language helps align expectations, improve study reproducibility, and inform policy decisions. Without shared understanding, efforts to study and apply psychedelics therapeutically risk confusion and fragmentation.
IUPHAR-review: The integration of classic psychedelics into current substance use disorder treatment models.
Pharmacological Research January 1, 2024 David B. Yaden, Andrea P Berghella, Peter S. Hendricks et al. 12 citations
Classic psychedelic-assisted therapies show initial promise for treating substance use disorders (SUDs) and may become legally available options. This article describes how these therapies could fit within current evidence-based SUD treatments, suggesting broad compatibility with most mainstream clinical approaches.
A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research
Psychedelic Medicine January 20, 2025 Marianna Graziosi, Gabrielle Agin-Liebes, Mary P Cosimano et al. 9 citations
Psilocybin and other serotonergic psychedelics are used in research settings with safety measures including controlled environments, staff presence, screening, and psychoeducation. An analysis of study materials from psilocybin trials over the past two decades found that psychoeducation documents varied but commonly emphasized biological and physical safety, psychological safety and well-being, aspects of setting, and the potential for expectancies. The materials prioritized biological and psychological safety across all sites. The authors also identified elements unrelated to safety that may contribute to participant expectancies and suggest these extrapharmacological factors be studied systematically to maximize safety while minimizing extraneous expectancies.
Psychedelic medicine in psychiatry residency training: a survey of psychiatric residency program directors.
Int Rev Psychiatry September 11, 2024 Mary E. Yaden, Terence H. W. Ching, Noam Goldway et al. 2 citations
A survey of US psychiatry residency training directors found that most (64%) favor adding more time for psychedelic education, yet many worry about a lack of educational materials (54%) and limited faculty to teach the content (46%). Almost all programs (94%) expressed some interest in a standardized curriculum in psychedelic medicine. Training directors recognize current offerings are limited and want more support to meet the coming demand for education in this emerging field.
Roland R. Griffiths, psychopharmacology pioneer: Abuse liability, alcohol, nicotine, caffeine, benzodiazepines, and psychedelics.
Journal of psychopharmacology (Oxford, England) January 1, 2026 Jack E Henningfield, Frederick S. Barrett, Suzette M Evans et al.
Roland R. Griffiths was a highly influential scientist in behavioral and neuropsychopharmacology, known for his rigorous research on abuse liability of substances including alcohol, benzodiazepines, caffeine, tobacco, and psychedelics. This review, authored by his former mentees and collaborators, describes his methodical approach to research, his inclusive and collegial mentoring style, and his role in advancing scientific methods for abuse liability assessment, policy, and regulation. His work culminated in the establishment of the Johns Hopkins Center for Psychedelic and Consciousness Research, reflecting his curiosity-driven, humanity-serving science that continues to inspire innovation.